Live Breaking News & Updates on கிறிஸ்டியன் ஹமாச்சர்
Stay updated with breaking news from கிறிஸ்டியன் ஹமாச்சர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Chutes & Ladders—Genzyme vet Sherblom joins ReForm amid subcutaneous delivery shift fiercebiotech.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercebiotech.com Daily Mail and Mail on Sunday newspapers.
Biocon to deliver advanced cancer therapies across 30 countries Biocon to deliver advanced cancer therapies across 30 countries 05 February 2021 | News Image Credit: shutterstock.com Biocon Biologics Ltd, a fully integrated ‘pure play’ biosimilars company and a subsidiary of Biocon Ltd has signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP). The partnership is a significant step in delivering advanced cancer therapies to patients who need them the most and ensuring equitable access to high-quality biosimilars in low- and middle-income countries (LMICs). ....
Biocon Biologics to offer its Oncology Biosimilars through Cancer Access Partnership in over 30 countries Posted On: 2021-02-04 04:58:01 (Time Zone: Arizona, USA) Biocon Biologics Ltd., a fully integrated pure play biosimilars company and a subsidiary of Biocon Ltd. (BSE code: 532523, NSE: BIOCON), has signed an agreement with the Clinton Health Access Initiative (CHAI) to expand access to lifesaving cancer biosimilars in over 30 countries in Africa and Asia as a part of the Cancer Access Partnership (CAP). The partnership is a significant step in delivering advanced cancer therapies to patients who need them the most and ensuring equitable access to high-quality biosimilars in low- and middle-income countries (LMICs). ....
Delay in award of tenders, higher entry barriers to new markets restricting growth: Kiran Mazumdar Shaw January 25, 2021 × The nature of these challenges is not linked to the fundamentals of the business: Biocon chief In slightly over a year since its inception, Biocon Biologics, a subsidiary of Biocon, has seen its valuation grow to $4.17 billion. In an interview with BusinessLine, Kiran Mazumdar Shaw, the Executive Chairperson of Biocon and Biocon Biologics talks about the challenges ahead for its subsidiary and the reasons for the sudden exit of its MD, Christiane Hamacher. Excerpts: What led to subdued performance of the generics business in Q3? What plans do you have to revive growth in this business? ....